Researchers at the University of Sheffield, led by Professors Bazbek Davletov and Andrew Peden, have developed cell-based assays that could replace animal testing in the manufacture of clostridial toxin-based medicines, such as Botox and tetanus vaccines.
Currently, safety and potency testing of these powerful but dangerous toxins relies on animal assays, including the mouse LD50 test, which raises ethical and scientific concerns. The Sheffield team engineered human neuroblastoma cell linessensitive to these toxins, enabling precise, reliable, and more sensitive testing than traditional animal methods.
This breakthrough could become the new global standard for tetanus vaccine testing, with ten manufacturers already collaborating to validate the method under Good Manufacturing Practice (GMP) standards. Beyond tetanus, the approach has the potential to transform pharmaceutical safety testing by reducing and ultimately replacing animal use.
Credit: Mia Rozenbaum – Understanding Animal Research